Disclosure: Bullpen receives compensation from VersaBank for research coverage. VersaBank is also an IR client of LodeRock Advisors, an affiliate of Bullpen.

TSX
1D %
YTD %
35,217.06
1.2%
10.5%
TSXV
1D %
YTD %
1,020.76
1.6%
2.8%
S&P 500
1D %
YTD %
7,584.31
0.4%
10.6%
NASDAQ
1D %
YTD %
26,830.96
0.1%
15.5%
US 10Y
1D
YTD
4.48
2 bps
31 bps
DJIA
1D %
YTD %
51,561.93
1.7%
6.6%
CA 10Y
1D
YTD
3.44
0 bps
0 bps
CAD/USD
1D %
YTD %
0.719
0.1%
1.3%

WHAT'S ON TAP

HOT OFF THE PRESS

Productivity sinks

With the weak GDP print last week, it should come as no surprise that Q1 labour productivity continues to struggle - falling 0.5% versus expectations for a 0.7% gain…

… which was compounded by growth in hourly compensation, pushing unit labour costs up 1.4% - the fourth straight sequential increase.

Investors may be wrong on TransAlta’s $1B deal

TransAlta (TA) dropped over 10% after announcing its $1B acquisition of two peaker plants in Colorado, which builds on its growing gas footprint

and upgrades the overall portfolio, with the acquired assets contracted for the next 27 years. Investors didn’t like the financing package, with the company issuing $350M of stock at 10x EBITDA to buy at 12.5x EBITDA…

… which looks dilutive until you do the napkin math on FCF impact. Driven by a weak outlook for Alberta power prices, management is calling for $400M of FCF at the midpoint this year

and expects $45M of run-rate FCF from the deal, with potential upside from incentive payments. That’s an ~11% increase in cash flow, funded by a ~6% increase in share count - so ~5% accretive to FCF per share.

That math works all the way up to $735M of base FCF, meaning Alberta spot prices would need to hit ~$220/MWh before the deal becomes dilutive - given a $1/MWh increase drops $2M to the bottom line…

… which is a scenario I don’t think anyone would mind, as the company would be printing cash. Interesting deal, I think the market might have this one wrong.

VERSABANK

VersaBank (VBNK) reported Q2 results that edged past estimates, supported by US expansion - with an additional US$150M of structured receivable program funding…

… and management guiding to another US$650M+ in H2. That should drive a low-20s efficiency ratio south of the border by year end, translating to ROE improvement…

which the market is starting to price in, with VBNK now trading at 1.5x book value after a ~10% post-print run in shares.

The commercialization of its real-time SRP could bring additional upside, which we cover in the full report:

VersaBank Q2-26 Earnings.pdf

VersaBank Q2-26 Earnings

1.12 MBPDF File

ON OUR RADAR

GAINERS & LOSERS

Coveo (CVO)
1D %
YTD %
4.41
5.3%
33.4%
TransAlta (TA)
1D %
YTD %
18.00
10.4%
3.7%
Docebo (DCBO)
1D %
YTD %
24.67
6.2%
19.1%
Transcontinental (TCL-A)
1D %
YTD %
4.71
9.8%
-
Constellation (CSU)
1D %
YTD %
2,901.56
5.5%
12.1%
Celestica (CLS)
1D %
YTD %
591.01
7.1%
45.6%

Transcontinental (TCL-A) sold off 10% on its Q2 results, which missed on both revenue and EPS despite help from M&A - with a slowdown in organic volumes

which has been a consistent theme since 2023. Following the company’s $2.2B packaging unit divestiture

the print and media business is the sole focus for investors, which could result in choppiness until they settle on a fair value.

EARNINGS

YESTERDAY’S EARNINGS
Company Actual Consensus
🇨🇦 Transcontinental (TCL-A) 0.19 0.20
🇨🇦 Canaccord (CF) 0.48 0.31
🇨🇦 Saputo (SAP) 0.41 0.39

Was this forwarded to you? Join 10,000+ investors reading The Morning Meeting by clicking the button below.

About Bullpen: Bullpen Finance Inc. publishes content on Canadian markets and provides paid research coverage of select Canadian issuers. Bullpen is paid in cash by covered issuers, does not accept stock or options, does not hold positions in covered securities, and does not conduct investment banking business. Bullpen and LodeRock Advisors Inc. are affiliated; LodeRock provides investor relations services to issuers, some of whom are covered by Bullpen Research. When a post discusses a covered issuer, a specific disclosure appears at the top of the post. This post is published for general information purposes. It is not personalized investment advice and is not tailored to any individual reader’s circumstances. Bullpen is not a registered investment adviser or dealer. For full disclosures, including analyst certification, jurisdictional statements, and conflict of interest policies, please see our Legal & Disclosures section on our website.

You might be interested in…